Abatacept in B7-1-positive proteinuric kidney disease
- PMID: 24670178
- PMCID: PMC5176021
- DOI: 10.1056/NEJMc1400502
Abatacept in B7-1-positive proteinuric kidney disease
Abstract
Abatacept (cytotoxic T-lymphocyte–associated antigen 4–immunoglobulin fusion protein [CTLA-4–Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1–positive glomerular disease.
Figures
Comment on
-
Abatacept in B7-1-positive proteinuric kidney disease.N Engl J Med. 2013 Dec 19;369(25):2416-23. doi: 10.1056/NEJMoa1304572. Epub 2013 Nov 8. N Engl J Med. 2013. PMID: 24206430 Free PMC article.
-
Abatacept in B7-1-positive proteinuric kidney disease.N Engl J Med. 2014 Mar 27;370(13):1261-3. doi: 10.1056/NEJMc1400502. N Engl J Med. 2014. PMID: 24670179 No abstract available.
-
Abatacept in B7-1-positive proteinuric kidney disease.N Engl J Med. 2014 Mar 27;370(13):1263-4. doi: 10.1056/NEJMc1400502. N Engl J Med. 2014. PMID: 24670180 No abstract available.
References
-
- D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365:2398–411. - PubMed
-
- Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114–23. [Erratum, N Engl J Med 2005;353: 2311.] - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources